Skip to content
RaiseKit
VCsFundsInvestmentsStart freePricing
RaiseKit

The most comprehensive database of web3 VCs. Built and maintained by AI agents.

Directory

  • VCs
  • Funds
  • Investments
  • Writing
  • Funding
  • Sectors
  • Geography

Resources

  • RSS Feed
  • Changelog
  • Search
  • Compare VCs
  • Reports
  • Activity
  • Deploying

Subscribe

Weekly digest of VC insights and funding rounds.

Subscribe to digest →

© 2026 RaiseKit. Data updated nightly by AI agents.

PrivacyTermsSupportDelete accountRSS
  1. Sectors
  2. /Therapeutics

Therapeutics

100 VCs and 9 funds investing in Therapeutics

VCs investing in Therapeutics

Alex Morgan

Partner

88%

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

IncubationPre-SeedSeed

Zosia van Eesteren

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Zosia van Eesteren invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Wim Schimmel

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wim Schimmel is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Wessel van 't Klooster

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wessel van 't Klooster invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Varsha Ram Balapa

Climate Specialist - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Varsha Ram Balapa is listed in a Climate Specialist - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Tristan Maguet

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tristan Maguet invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Tom Klein Robbenhaar

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tom Klein Robbenhaar invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Susana Amorim

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Susana Amorim invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stephanie Mooij

Head of Responsible Investment - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephanie Mooij is listed in a Head of Responsible Investment - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Stephan Wachtveitl

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephan Wachtveitl invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stefan Luzi

Partner Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stefan Luzi invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stacey Vrijhof

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stacey Vrijhof is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Sonia Hallen

Investment Manager Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Sonia Hallen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Silke Kranz

Investment Manager - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Silke Kranz invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Senay Sarsik

Office Manager Frankfurt - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Senay Sarsik is listed in a Office Manager Frankfurt - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Romy Wiering

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Romy Wiering is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Robert Stein

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Robert Stein invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rik Maerten

Junior Fund Controller - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rik Maerten is listed in a Junior Fund Controller - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Redmar Koene

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Redmar Koene invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Raphael Arndt

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Raphael Arndt invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rafael Natanek

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rafael Natanek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pommeline Korstanje

Associate Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pommeline Korstanje invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pieter van der Meer

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pieter van der Meer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pheline Mulitze

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pheline Mulitze invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Paulien Schippers

Finance Manager - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Paulien Schippers is listed in a Finance Manager - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Oksana van Vliet

Legal & AML/KYC counsel - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Oksana van Vliet is listed in a Legal & AML/KYC counsel - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Nellie Johnson

Executive Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Nellie Johnson is listed in a Executive Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Michel Verhoog

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Michel Verhoog invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Max Steeman

Associate - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Max Steeman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Martin von Berg

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Martin von Berg invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Marloes Herbrink

Finance Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marloes Herbrink is listed in a Finance Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Marion Pouillard

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marion Pouillard invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Luna van den Brink

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Luna van den Brink is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Ludo Suykerbuyk

General Counsel & Compliance Officer - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ludo Suykerbuyk is listed in a General Counsel & Compliance Officer - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Lara Hilgert

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Lara Hilgert invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Katharina Mono

ESG & Impact Analyst - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Katharina Mono is listed in a ESG & Impact Analyst - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kate Ebbenhorst

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kate Ebbenhorst is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kasia Lorek

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kasia Lorek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Karthik Bolisetty

Investment Manager Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Karthik Bolisetty invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Josephine Bogaerts

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Josephine Bogaerts invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Muijrers

General Partner Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Muijrers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Heldens

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Heldens invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jelte Goettsch

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jelte Goettsch invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jasper van Gorp

Managing Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jasper van Gorp invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Janke Dittmer

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Janke Dittmer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jan Willem Bakker

Head of Investor Relations / Partner - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jan Willem Bakker is listed in a Head of Investor Relations / Partner - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Iskander Shadid

Junior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Iskander Shadid invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hugo de Bruin

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hugo de Bruin invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Henry Zubaida

Investment Director Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Henry Zubaida invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hein Ploegmakers

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hein Ploegmakers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Giel Modderman

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Giel Modderman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Geoff Pardo

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Geoff Pardo invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edwin de Graaf

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edwin de Graaf invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edward Hanlon

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edward Hanlon invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Dirkjan Beugelsdijk

CFO - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Dirkjan Beugelsdijk is listed in a CFO - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Christiaan Sap

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Christiaan Sap is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Chris Allen

Senior Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Chris Allen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Camille Sinkora

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Camille Sinkora invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Boyd Rutten

Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Boyd Rutten invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Besmire Ahmati

Senior Associate Investor Relations & Fundraising - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Besmire Ahmati is listed in a Senior Associate Investor Relations & Fundraising - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Arthur Franken

General Partner Healthtech/Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Arthur Franken invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Ariane de Marcillac

Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ariane de Marcillac invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Olga Ziessen

Head Support Services

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Olga Ziessen is listed in a Head Support Services capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Philippe van Santen

Facility Manager

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Philippe van Santen is listed in a Facility Manager capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Chelle Tjabring

Senior Executive Assistant

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Chelle Tjabring invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Marijana Stojanovic

Receptionist

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Marijana Stojanovic is listed in a Receptionist capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Tess Keg

Senior Executive Assistant

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Tess Keg invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Britt Inga Emerson

Senior Executive Assistant, Investor Relations (US)

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Britt Inga Emerson is listed in a Senior Executive Assistant, Investor Relations (US) capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Tineke Duijn

Office Assistant

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Tineke Duijn is listed in a Office Assistant capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Dragana Dragusin

Executive Assistant

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Dragana Dragusin invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Alicia Dortona

Office Manager

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Alicia Dortona is listed in a Office Manager capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Danielle de Magalhães

Executive Assistant

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Danielle de Magalhães invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Rachelle Young

Investor Relations Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Rachelle Young is listed in a Investor Relations Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Maureen Wouters

Paralegal

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Maureen Wouters is listed in a Paralegal capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Patricia Vonk

AML/KYC Manager

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Patricia Vonk invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Viktorija Vodilovska

AI Specialist

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Viktorija Vodilovska is listed in a AI Specialist capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Iris Veldman

Deal Counsel

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Iris Veldman is listed in a Deal Counsel capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Pascal van Wees

Finance Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Pascal van Wees is listed in a Finance Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Thijs van Egmond

Legal Counsel

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Thijs van Egmond is listed in a Legal Counsel capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Devan Sequeira

IT Solution Architect

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Devan Sequeira is listed in a IT Solution Architect capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Walter Schram

Finance Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Walter Schram is listed in a Finance Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Francine MacLeod

HR Administrator

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Francine MacLeod invests or supports investments through Forbion's published strategy: Invest globally in companies transforming human health and the bioeconomy, from company creation and early stage through growth.

SeedEarly StageGrowth

Stijn Jochemsen

Finance Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Stijn Jochemsen is listed in a Finance Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Marnix Groot

Fund Controller

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Marnix Groot is listed in a Fund Controller capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Baris Duvan

Senior Paralegal

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Baris Duvan is listed in a Senior Paralegal capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Bart de Jong

Finance Manager

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Bart de Jong is listed in a Finance Manager capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Vincent Conijn

Senior Associate, Impact & ESG

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Vincent Conijn is listed in a Senior Associate, Impact & ESG capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Lior Alperovich

Marketing & Communications Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Lior Alperovich is listed in a Marketing & Communications Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Joost de Rijk

Investor Relations Director

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Joost de Rijk is listed in a Investor Relations Director capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Marc van Voorst tot Voorst

Head of Public Affairs

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Marc van Voorst tot Voorst is listed in a Head of Public Affairs capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Arjan Oosterheert

Head of Tax

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Arjan Oosterheert is listed in a Head of Tax capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Cyril Lesser

Vice President Finance - Funds

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Cyril Lesser is listed in a Vice President Finance - Funds capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Jennifer Fritzsche

Vice President Finance

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Jennifer Fritzsche is listed in a Vice President Finance capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Silva Dezelan

Head of Impact and ESG

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Silva Dezelan is listed in a Head of Impact and ESG capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Laura Asbjornsen

Head of Marketing & Communications

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Laura Asbjornsen is listed in a Head of Marketing & Communications capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Alice Vickers

Venture Advisor

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Alice Vickers is listed in a Venture Advisor capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Feike Sijbesma

Senior Advisor

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Feike Sijbesma is listed in a Senior Advisor capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Floor Saris

Advisor

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Floor Saris is listed in a Advisor capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Liz Rodgers

Advisor

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Liz Rodgers is listed in a Advisor capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Steen Riisgaard

Advisor

80%

Forbion

Check: Forbion does not publish one standard current check-size range across its funds on the official site.

Steen Riisgaard is listed in a Advisor capacity at Forbion. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedEarly StageGrowth

Funds focused on Therapeutics

Forbion

Naarden, Netherlands

109 people0 investments

Gilde Healthcare

Utrecht, Netherlands

61 people0 investments

NLC Health Ventures

Amsterdam, Netherlands

37 people0 investments

Wellington Partners

Munich, Germany

23 people0 investments

Kurma Partners

Paris, France / Munich, Germany

22 people0 investments

BioGeneration Ventures

Naarden, Netherlands

20 people0 investments

Newton Biocapital

Brussels, Belgium and Tokyo, Japan

15 people0 investments

V-Bio Ventures

Ghent, Belgium

7 people0 investments

Vesalius Biocapital

Luxembourg

5 people0 investments